Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology firm focused on developing and manufacturing cutting-edge diagnostic solutions catering to both medical and food industries. The company specializes in proprietary testing methods aimed at metabolic diseases, gastrointestinal disorders, and food intolerances, positioning itself to significantly enhance healthcare outcomes and diagnostic precision. With a commitment to addressing unmet medical needs, Biomerica capitalizes on strategic research partnerships and advanced technology integration, facilitating growth in the dynamic diagnostics market. Its patient-centric strategy further underscores the potential for transformative improvements in global healthcare diagnostics, making it a compelling prospect for institutional investors.
| Revenue (TTM) | $4.45M |
| Gross Profit (TTM) | 362,000 |
| EBITDA | $-5.24M |
| Operating Margin | -175.20% |
| Return on Equity | -112.10% |
| Return on Assets | -52.30% |
| Revenue/Share (TTM) | $1.53 |
| Book Value | $0.82 |
| Price-to-Book | 3.90 |
| Price-to-Sales (TTM) | 2.38 |
| EV/Revenue | 2.545 |
| EV/EBITDA | -5.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 16.80% |
| Shares Outstanding | $4.59M |
| Float | $3.97M |
| % Insiders | 21.76% |
| % Institutions | 2.73% |
Volatility is currently expanding
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2026 (“Fiscal 2026”).
IRVINE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (“Biomerica” or the “Company”), a developer and manufacturer of diagnostic test systems, today announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the Company's common stock at a price of $1.60 per share, expected to provide approximately $2.23 million in gross proceeds to the Company.
Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS program Auto-renewing Master Services Agreement engages Biomerica's integrated development and manufacturing platform, reflecting the Company's CDMO strategy as a capital-efficient, parallel revenue stream alongside its core inFoods® IBS program
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world's largest GI medical conference, May 2–5, 2026, in Chicago
Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended February 28, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BMRA and any ticker you trade — then tracks every position and per-strategy win rate.
